{"product_id":"biogen-five-forces-analysis","title":"Biogen Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBiogen faces intense rivalry from big pharma and specialty biotech, tempered by strong patent-protected revenue streams and high barriers for new entrants due to R\u0026amp;D costs and regulatory hurdles; supplier and buyer power are moderate, while substitutes and biosimilars pose growing long-term risks. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Biogen’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Biological Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized biological inputs—proprietary cell lines, media and reagents—are sourced from few vendors, giving suppliers strong leverage; supplier concentration risk rose after 2023 supply-chain shocks. As of late 2025, even a single-month disruption could halt Leqembi production, risking revenue loss measured in tens of millions per batch. Switching costs include costly regulatory re-validation (BLA supplements, stability studies) and 6–18 months requalification time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Contract Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiogen relies heavily on third-party Contract Manufacturing Organizations (CMOs) to scale production for new neurological therapies and its biosimilar pipeline; in 2024 roughly 35% of its biologics output was CMO-produced, raising supplier leverage.\u003c\/p\u003e\n\u003cp\u003eHigh-end CMOs operate near full capacity—industry utilization ~85% in 2024—letting them press higher pricing and tighter lead times at renewals, which raised Biogen’s CMO costs by an estimated 6–9% in 2024.\u003c\/p\u003e\n\u003cp\u003eSpecialized fill-finish services are scarce and concentrated among few providers, increasing switching costs and giving those service suppliers elevated bargaining power over Biogen’s supply continuity and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Intellectual Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 the global market for specialized neurodegenerative researchers and data scientists remained extremely tight, with estimated vacancy rates \u0026gt;12% in biotech hubs and median total comp for top talent rising ~18% year-over-year to $280k–$420k. Biogen competes with Big Pharma and nimble startups for skills in complex trial design and AI-driven discovery, so elite scientists can demand premium pay and dedicated computational resources. This scarcity makes high-end intellectual capital a powerful supplier, directly driving R\u0026amp;D cost per program higher and speeding project prioritization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Laboratory Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced proteomics and genomic sequencers are concentrated: Illumina (now part of Illumina Inc.) and Thermo Fisher Scientific held ~65% of sequencing\/proteomics market share in 2024, with key patents and proprietary software, giving them durable pricing power.\u003c\/p\u003e\n\u003cp\u003eLong-term service contracts (avg. 5–7 years) and tied reagent\/software ecosystems raise switching costs; Biogen’s dependence on these platforms for its R\u0026amp;D pipeline sustains supplier leverage and margin pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~65% market share (2024)\u003c\/li\u003e\n\u003cli\u003eAverage service contracts 5–7 years\u003c\/li\u003e\n\u003cli\u003eHigh switching costs: proprietary software + reagents\u003c\/li\u003e\n\u003cli\u003eSuppliers exert sustained pricing power on Biogen\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Logistics for Cold Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiogen’s biologics need strict cold-chain handling, and only a few global logistics firms (DHL, Kuehne+Nagel, UPS Healthcare) offer end-to-end validated cold solutions, giving suppliers pricing leverage.\u003c\/p\u003e\n\u003cp\u003eIn 2025 rising fuel costs and tighter trade rules let providers add fuel surcharges and infrastructure fees; global cold-chain market grew to about $24.5B in 2024, increasing provider bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew qualified providers: high dependence\u003c\/li\u003e\n\u003cli\u003eCold-chain market ~ $24.5B (2024)\u003c\/li\u003e\n\u003cli\u003eFuel\/infrastructure fees rose with 2025 regs\u003c\/li\u003e\n\u003cli\u003eSupplier power increases per-shipment costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Cripples Biologics: CMOs, Cold-Chain \u0026amp; Sequencers Drive Costs Up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong power: concentrated CMOs and specialized reagents\/sequencers give Biogen high switching costs (6–18 months; BLA re-validation) and pricing pressure; 2024 CMO share ~35% of Biogen biologics, industry utilization ~85% raised CMO costs ~6–9%. Cold-chain market ~$24.5B (2024) and sequencers (~65% market share in 2024) further bolster supplier leverage, while talent shortages pushed top-scientist pay +18% to $280k–$420k (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share (Biogen 2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry utilization (2024)\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO cost rise (2024)\u003c\/td\u003e\n\u003ctd\u003e6–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market (2024)\u003c\/td\u003e\n\u003ctd\u003e$24.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencer market share (2024)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop scientist pay (2025)\u003c\/td\u003e\n\u003ctd\u003e$280k–$420k (+18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Biogen, this Porter's Five Forces overview uncovers competitive drivers, buyer\/supplier power, entry barriers, substitutes, and disruptive threats shaping Biogen’s market position and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary for Biogen—quickly spot competitive pressures and prioritize strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidated Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidated Pharmacy Benefit Managers (PBMs) in the US—with three firms covering ~80% of commercial lives as of 2025—wield heavy bargaining power, pushing rebates that cut Biogen’s net prices for MS and Alzheimer’s drugs by 25–40% on average; for high-cost neurotherapies, negotiated rebates often exceed 40% on list price. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Reimbursement Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cppublic health systems and medicare press biogen via centralized buying price negotiation cutting list prices rebates in drug spending negotiations target top biologics giving payers leverage over pricing.\u003e\n\u003cpthe inflation reduction act lets medicare negotiate on select high-spend biologics starting and expanding by biogen faces potential single-digit to mid percentage price cuts report margin pressure must link prices outcomes data.\u003e\n\u003c\/pthe\u003e\u003c\/ppublic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Technology Assessment Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphealth technology assessment bodies like nice and icer set cost-effectiveness thresholds that shape payer coverage benchmarks can make or break biogen launches. a negative hta verdict bar access to national formularies major insurers cutting potential market revenue lost in projected uk sales after past restrictions. their guidance anchors both public commercial pricing negotiations forcing steep discounts restricted indications.\u003e\n\u003c\/phealth\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp hospital networks now owning roughly of us beds as press biogen for bulk discounts and outcomes-based pricing when new rare-disease drugs launch using formularies in ehrs to steer physician prescribing toward preferred products.\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% US hospital beds in consolidated systems (2024)\u003c\/li\u003e\n\u003cli\u003eNetworks demand volume discounts, risk-sharing on launch\u003c\/li\u003e\n\u003cli\u003eEHR formulary placement shifts physician choices\u003c\/li\u003e\n\u003cli\u003eHigh patient volume = leverage for better financial terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups for Alzheimer’s and spinal muscular atrophy (SMA) strongly influence Biogen’s market access: Alzheimer’s groups helped drive Medicare coverage debates after Aduhelm’s 2021 approval, and SMA groups supported wide payer access to nusinersen (Spinraza) since 2016.\u003c\/p\u003e\n\u003cp\u003eThey back access but demand transparency and affordability, pushing Biogen to sustain patient-assistance programs that in 2024 subsidized millions in co-pays and free drug access for qualifying patients.\u003c\/p\u003e\n\u003cp\u003eTheir lobbying and media mobilization can sway legislators and public payers; for example, coordinated campaigns influenced state Medicaid coverage policies for orphan drugs in 2023–2025.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eAdvocacy drove Aduhelm Medicare debates (2021) and SMA payer wins (2016–ongoing)\u003c\/li\u003e\n\u003cli\u003e2024 assistance programs covered millions in cost support\u003c\/li\u003e\n\u003cli\u003eCan shift state Medicaid and congressional attention (2023–2025)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Control Pricing: PBMs, Medicare Cuts \u0026amp; Hospital Discounts Squeeze Drug Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: three PBMs cover ~80% commercial lives (2025), driving typical rebates of 25–40% and \u0026gt;40% on high‑cost neurotherapies; Medicare negotiation (IRA) and HTA benchmarks ($100k–$150k\/QALY ICER; £20k–£30k\/QALY NICE) force single‑digit to mid‑teens price cuts; hospital systems (~40% US beds, 2024) and patient groups push discounts, outcomes contracts, and assistance programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003e~80% commercial (2025)\u003c\/td\u003e\n\u003ctd\u003e25–40% rebates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/IRA\u003c\/td\u003e\n\u003ctd\u003eNegotiations expanded 2023–2026\u003c\/td\u003e\n\u003ctd\u003emid‑teens cuts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~40% beds (2024)\u003c\/td\u003e\n\u003ctd\u003ebulk discounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBiogen Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Biogen Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders or sample content.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the full, professionally formatted file you can download and use the moment you buy, covering supplier power, buyer power, competitive rivalry, threat of substitutes, and barriers to entry.\u003c\/p\u003e\n\u003cp\u003eNo mockups or edits—what you see is the final deliverable, ready for immediate application in investment or strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746911859065,"sku":"biogen-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biogen-five-forces-analysis.png?v=1772193200","url":"https:\/\/matrixbcg.com\/products\/biogen-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}